17 results about "Isonicotinamide" patented technology

A multistep continuous flow synthesis method for the manufacture of isonicotinyl-hydrazide (Isoniazid) comprising reacting 4-cyano pyridine with NaOH at a specified molar ratio and temperature range to produce the intermediate isonicotinamide, which intermediate is reacted with hydrazine hydrate, without isolation thereof, at a specified molar ratio and temperature range to produce isonicotinyl-hydrazide (Isoniazid) in a yield greater than about 90%.

The invention discloses an acacetin and isonicotinamide eutectic, a preparation method, a composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention discloses an eutectic substance formed by acacetin and isonicotinamide, and the molecular formula of the eutectic substance is (C16H12O5). (C6H6N2O), the invention relates to a preparation method of a cocrystal of acacetin and isonicotinamide. The acacetin and isonicotinamide eutectic is used as an active ingredient of a medicine and is applied to preparation of medicines for resisting oxidation, resisting inflammation, resisting viruses, resisting tumors, resisting rheumatism, easing pain, protecting the liver, regulating immunity, treating osteoporosis and treating cardiovascular and cerebrovascular diseases.

The invention discloses a method for determining the residual quantity of petroleum ether in an isonicotinamide benzonate bulk drug by using capillary gas chromatography, and belongs to the technical field of drug analysis. According to the method, an external standard method is adopted for quantification, a 6% cyanopropyl phenyl-94% dimethyl polysiloxane capillary column is used as a chromatographic column, and an FID detector is adopted for detection; the residual quantity of the petroleum ether is the total residual quantity of normal hexane, 2-methylpentane and 3-methylpentane in the petroleum ether. The method disclosed by the invention is good in specificity, good in linearity, reliable in accuracy and high in sensitivity; the gas chromatographic method can be used for rapidly, effectively, accurately and reliably separating and detecting the residual amount of petroleum ether in the isopropylamine bulk drug, and is beneficial to improving the product quality of the isopropylamine bulk drug and improving the medication safety of a patient.

Stable crystal forms comprising lithium ions and the conjugate base of an organic acid which is in the form of anhydrous coordination polymer that exhibit improved in vivo performance with respect to lithium carbonate.

The invention provides a method for synthesizing chiral N-(4-chloro-2-(hydroxy(phenyl)methyl)phenyl)isonicotinamide (anti-inversion amine). The method uses N-(2-benzoyl-4-chlorophenyl)isonicotinamide as a raw material, uses a complex formed in situ by metal iridium and a phenylethylamine skeleton PNN ligand as a catalyst, methanol as a solvent, and potassium carbonate as an alkali additive. A hydrogenation reaction occurs under this homogeneous catalytic system, and N-(4-chloro-2-(hydroxy(phenyl)methyl)phenyl)isonicotinamide is obtained with a yield of >99% and an ee value of >99%. The method has high activity, mild conditions, and high industrial application value.

The invention provides a metal organic framework material as well as a preparation method, application and separation method thereof, and the metal organic framework material is prepared by dissolving metal cations, N, N '-(1, 4-phenylene) diisonicotinamide and an organic ligand in an organic solvent according to a molar ratio of 1: (0.1-2): (0.1-2) and then carrying out solvothermal reaction, the structural formula of the organic ligand is as follows: in the formula # imgabs0, R is one of H, CH3, NH2, F, Cl, Br and OH; amido and an R group are contained in a pore channel of the metal organic framework material. When the metal organic framework material is used as an adsorbent for separating carbon dioxide and nitrogen, efficient separation of carbon dioxide and nitrogen under a dry condition or a high-humidity condition, such as 75% RH moisture, can be realized.

The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl) isonicotinamide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl) isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers.

The invention belongs to the technical field of nitrogen fertilizer inhibitors, and particularly relates to a dual synergistic nitrogen fertilizer inhibitor and a preparation method and application thereof, anhydrous copper nitrate, 2, 5-thiophenedicarboxylic acid and N, N '-(methylene bis (1, 4-phenyl)) diisonicotinamide are used as main components, and the main components are calcined in a reaction kettle to form the dual synergistic nitrogen fertilizer inhibitor. The dual synergistic nitrogen fertilizer inhibitor has the advantages of simple preparation method, high inhibition efficiency, good safety and the like, has better inhibition effect on urease activity, can denature and inactivate the structure of urease, delays the conversion from urea nitrogen to ammonium nitrogen, achieves the effect of inhibiting the urease activity, delays the conversion from ammonium nitrogen to nitrate nitrogen, and has good application prospects. The effect of inhibiting the activity of the nitrifying bacteria is achieved.

The invention relates to the field of pharmacy, in particular to a pharmaceutical composition containing N (3-(2-(2-hydroxyethoxy)-6-morpholinopyridine-4-yl)-4-methylphenyl)-2-(trifluoromethyl) isonicotinamide or pharmaceutically acceptable salt of the N (3-(2-(2-hydroxyethoxy)-6-morpholinopyridine-4-yl)-4-methylphenyl)-2-(trifluoromethyl) isonicotinamide. The invention also provides methods for preparing the pharmaceutical compositions for oral administration and methods of treatment with the pharmaceutical compositions.

The invention belongs to the technical field of crystal form medicine molecules, and particularly relates to a rosmeltirol crystal form and a preparation method thereof. The invention provides two crystal forms of rosmeltirol, and the crystal forms of rosmeltirol-nicotinamide-methanol have characteristic peaks at least at the positions of 6.2 + / -0.2 degrees, 14.4 + / -0.2 degrees, 21.5 + / -0.2 degrees, 22.4 + / -0.2 degrees, 24.3 + / -0.2 degrees, 26.5 + / -0.2 degrees and 27.4 + / -0.2 degrees in an X-ray diffraction spectrum represented by 2 theta by using Cu-K alpha radiation; according to the crystal form, Cu-K alpha radiation is used, and an X-ray diffraction spectrum represented by 2 theta has characteristic peaks at least at the positions of 12.0 + / -0.2 degrees, 15.6 + / -0.2 degrees, 17.8 + / -0.2 degrees, 19.9 + / -0.2 degrees, 20.8 + / -0.2 degrees and 28.1 + / -0.2 degrees. The rosmeltirol crystal form is good in stability, almost free of hygroscopicity, high in solubility and high in medicinal value.

The application discloses a zinc(II)-calix[4]arene complex single crystal and a preparation method and application thereof, and belongs to the technical field of coordination chemistry and adsorbents, and provides a preparation method of the zinc(II)-calix[4]arene complex single crystal, which comprises the following steps: mixing a soluble zinc source, 5,11,17,23-tetra[(m-carboxylphenyl)azo]-25,26,27,28-tetrahydroxycalix[4]arene and N-(pyridin-4-yl)isonicotinamide in a solvent, and reacting to obtain the zinc(II)-calix[4]arene complex single crystal. The zinc(II)-calix[4]arene complex single crystal prepared by the application has rich amide functional groups in a three-dimensional framework structure, and has rich active adsorption sites, and has good UO2 2+ adsorption removal effect.

The invention provides a high-precision detection method for the content of related substances in an isoniazide injection. The content of four related substances including isonicotinamide, benzoyl hydrazine, 4-cyanopyridine and diisonicotinoyl hydrazine in the isoniazide injection can be accurately measured. The detection method comprises the following steps: S1, preparing a test solution and a mixed reference solution containing isoniazide and four related substances at the same time; s2, performing sample injection detection by using a high performance liquid chromatograph, performing sample injection mixing on the reference substance solution, and determining the retention time and the peak area of each related substance; and injecting the test solution, determining the peak appearance of each related substance according to the retention time, and calculating the content of each related substance through an external standard method. The detection method is high in sensitivity and durability, quantitative analysis can be carried out, the content of isoniazide, isonicotinamide, benzoyl hydrazine, 4-cyanopyridine and diisonicotinoyl hydrazine can be accurately detected, and a reasonable basis is provided for medicine quality control.

Provided in the present invention are a plurality of cocrystal forms of Resmetirom and isonicotinamide, a pharmaceutical composition containing the crystal forms, and the use of the crystal forms in the preparation of drugs for treating THR-β-mediated diseases.

The invention discloses an eutectic substance formed by combining chrysin (English name: Chrysin) and isonicotinamide (English name: Isonicotinamide) through a non-covalent bond as well as a preparation method and application of the eutectic substance. Specifically, the invention discloses an eutectic substance formed by chrysin and isonicotinamide, and the molecular formula of the eutectic substance is C15H10O4. C6H6N2O, the invention relates to a preparation method of a chrysin and isonicotinamide eutectic. The chrysin and isonicotinamide eutectic is applied to preparation of medicines with the effects of preventing and treating cardiovascular diseases, resisting oxidation, resisting cancer, resisting virus, resisting hypertension, reducing blood fat, reducing blood sugar, resisting bacteria, diminishing inflammation and the like.

The invention belongs to the technical field of aluminum foil formation, and discloses an amide-aluminum sulfate hydrated eutectic electrolyte for hydration treatment of a high-voltage electrode foil and application of the amide-aluminum sulfate hydrated eutectic electrolyte. The hydrated eutectic electrolyte is prepared by compounding aluminum sulfate and an amide compound (isonicotinamide, N-methyl nicotinamide or 2-pyrrolidone) according to a specific molar ratio, and the hydrated eutectic electrolyte is dissolved in high-purity water to form a stable eutectic system. Through the synergistic effect of the eutectic electrolyte, formation and densification of a hydration film (Al2O3.nH2O) on the surface of the aluminum foil are accelerated, and the technical problems that traditional hydration treatment is long in time (larger than or equal to 10 minutes), high in energy consumption, low in formation efficiency and multiple in oxidation film defect are solved. By applying the hydration treatment process, the hydration time can be shortened to 5-8 minutes, the formation efficiency is improved by 25-35%, the specific capacitance is improved by 1-5%, the leakage current is reduced by 15-25%, the energy consumption is reduced by 15-30%, the product quality and the production economy are remarkably improved, and the hydration treatment process is suitable for industrial production of the high-voltage electrode foil.